Skip to content

Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily for Trial Without Catheter in Acute Urinary Retention With Long Term Follow up

Randomized Trial Comparing Terazosin 5 mg Daily and Doxazosin GITS 4 mg Daily in the Successful Rate of Trial Without Catheter in Acute Urinary Retention With Long Term Follow up

Status
Terminated
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00563485
Enrollment
120
Registered
2007-11-26
Start date
2005-10-31
Completion date
2006-11-30
Last updated
2011-06-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Prostatic Hyperplasia, Urinary Retention

Keywords

Benign Prostatic Hyperplasia (BPH), Acute Retention of Urine (AUR)

Brief summary

The purpose of the study is to compare two alpha blockers, terazosin and doxazosin GITS, in achieving a successful TWOC after AUR due to BPH, among Chinese males in Hong Kong, and in delaying or avoiding a TURP.

Interventions

DRUGDoxazosin GITS (Cardura XL)

Sponsors

Hospital Authority, Hong Kong
Lead SponsorOTHER_GOV

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
MALE
Age
50 Years to No maximum

Inclusion criteria

* Aged 50 or above * Admitted for AUR due to BPH with PVR of 500 ml or more

Exclusion criteria

* Previous history of TURP * Use of alpha blockers within recent 8 months * Renal impairment (serum creatinine \>140 umol/l) * Poor premorbid state

Design outcomes

Primary

MeasureTime frame
Successful rate of Trial Without Catheter (TWOC) at phase 1At discharge after TWOC (at the end phase one)
Late failure of TWOC of, which is defined as recurrent of AUR or the need of invasive therapy among those who are successful in TWOC in phase 1From the end of phase one to eight months after successful TWOC (the end of phase 2)

Secondary

MeasureTime frame
Proportion of subjects with hypotension or symptoms related to hypotension after administration of treatment drug for TWOCFrom the time of treatment drug administration to the end of phase 1
Peak flow rate (Qmax), voided volume (Vcomp) and post-voided residue volume (PVR)At the end of phase I (discharge after TWOC) and at the end of phase 2

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026